Effect of mannitol on acute kidney injury induced by cisplatin.
Acute kidney injury
Cisplatin
Hydration
Mannitol
Nephrotoxicity
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
14
02
2020
accepted:
20
08
2020
pubmed:
31
8
2020
medline:
23
3
2021
entrez:
31
8
2020
Statut:
ppublish
Résumé
Acute kidney injury (AKI) is a frequent dose-limiting toxicity induced by cisplatin. Mannitol has been used in hydration protocols to mitigate this adverse event but its role remains controversial. The aim of this study is to define the impact of mannitol on AKI in patients receiving cisplatin. This retrospective observational study was conducted in cancer patients who received at least one dose of cisplatin between September 2010 and December 2016 at the Centre hospitalier de l'Université de Montréal. The primary outcome of this study was the comparison of all grade cisplatin-associated AKI between hydration protocols with or without mannitol. A total of 1821 patients were included of which 658 received mannitol whilst 1163 received hydration alone. The risk of all grade cisplatin-associated AKI was significantly lower for the mannitol group (Hazard Ratio (HR) = 0.62; 95% CI [0.42, 0.89]). This result was mainly driven by gynecologic (HR = 0.50), upper gastrointestinal (HR = 0.32), urinary tract malignancies (HR = 0.29) and lymphoma (HR = 0.33). No significant difference was seen for head and neck (HN), lung, germ cells and other cancers. However, HN cancers patients receiving mannitol had fewer grade 2 and 3 AKI. Significantly fewer AKI events were observed in HN, lung, upper gastrointestinal and urinary tract cancer when mannitol was added for cisplatin dose <75 mg/m Although the results were generally driven by a decrease of grade 1 AKI for most cancers, the greatest benefit of mannitol was seen with cisplatin doses lower than 75 mg/m
Identifiants
pubmed: 32862356
doi: 10.1007/s00520-020-05703-7
pii: 10.1007/s00520-020-05703-7
doi:
Substances chimiques
Antineoplastic Agents
0
Diuretics, Osmotic
0
Mannitol
3OWL53L36A
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2083-2091Subventions
Organisme : Université de Montréal
ID : Research grant from the Faculty of pharmacy
Références
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124
doi: 10.1097/MAJ.0b013e31812dfe1e
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609–619
doi: 10.1634/theoncologist.2016-0319
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007
doi: 10.1038/sj.ki.5002786
Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903–909
doi: 10.1007/s00280-008-0711-0
Morgan KP, Snavely AC, Wind LS, Buie LW, Grilley-Olson J, Walko CM, Weiss J (2014) Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother 48:863–869
doi: 10.1177/1060028014533303
Mach CM, Kha C, Nguyen D, Shumway J, Meaders KM, Ludwig M, Williams-Brown MY, Anderson ML (2017) A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J Clin Pharm Ther 42:286–291
doi: 10.1111/jcpt.12509
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518
doi: 10.3390/toxins2112490
Ostrow S, Egorin MJ, Hahn D et al (1981) High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73–78
pubmed: 6784924
Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats. Cancer Treat Rep 61:375–379
pubmed: 872137
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381
doi: 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J
Al-Sarraf M, Fletcher W, Oishi N et al (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31–35
pubmed: 6796269
Santoso JT, Lucci JA 3rd, Coleman RL et al (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18
doi: 10.1007/s00280-003-0620-1
Leu L, Baribeault D (2010) A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract 16:167–171
doi: 10.1177/1078155209346071
Morgan KP, Buie LW, Savage SW (2012) The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother 46:276–281
doi: 10.1345/aph.1Q333
McKibbin T, Cheng LL, Kim S et al. (2015) Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer
Williams RP, Jr., Ferlas BW, Morales PC, Kurtzweil AJ (2016) Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J Oncol Pharm Pract
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P (2019) A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. J Oncol Pharm Pract 25:875–883
doi: 10.1177/1078155218771461
Lobo DN, Stanga Z, Simpson JA et al (2001) Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci (Lond) 101:173–179
doi: 10.1042/cs1010173
Dumas M, de Gislain C, d’Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N (1990) Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 26:278–282
doi: 10.1007/BF02897230
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, U.S. Departement of Health and Human services, National Institutes of Health and National Cancer Institute. In. 2010
Cnaan A, Ryan L (1989) Survival analysis in natural history studies of disease. Stat Med 8:1255–1268
doi: 10.1002/sim.4780081009